RSCM
DAWN

Rock Springs Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Rock Springs Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-381,939
Closed -$6.44M – 137
2021
Q4 		$6.44M Buy
381,939
+5,500
+1% +$113K 0.15% 109
2021
Q3 		$8.93M Buy
376,439
+2,700
+0.7% +$64.7K 0.19% 110
2021
Q2 		$8.51M Buy
+373,739
New +$7.8M 0.17% 121

Other funds holding DAWN

CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rock Springs Capital Management's DAWN Position: Q1 2022 in Review

Rock Springs Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2022, closing a stake of 381,939 shares — an estimated $6.44M sold.

Rock Springs Capital Management first reported a position in DAWN in Q2 2021 and held it in 3 quarters. The position peaked at $8.93M in Q3 2021. 66 funds tracked by Wall St. Rank hold DAWN as of Q1 2022.

  • Rock Springs Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rock Springs Capital Management sold 381,939 Day One Biopharmaceuticals shares in Q1 2022, an estimated $6.44M.
  • Rock Springs Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Rock Springs Capital Management's Day One Biopharmaceuticals position peaked at $8.93M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2022.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.